A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

计划入组 12 人 · 首次发布于 2024 年 8 月 19 日

Pioglitazone Therapy for Chronic Granulomatous Disease

计划入组 3 人 · 首次发布于 2017 年 3 月 15 日

Gene Therapy for Chronic Granulomatous Disease

计划入组 3 人 · 首次发布于 2006 年 11 月 1 日

chronic kidney disease therapy

base-edited CD34+ HSPC (chronic granulomatous disease)

Chronic granulomatous disease therapy(Baxter International, Inc.)

Kineta Chronic Pain LLC

United States

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

Prime Medicine's PM359 Gains FDA RMAT Designation for p47phox-Deficient Chronic Granulomatous Disease

Prime Medicine Reports Breakthrough Clinical Data for First Prime Editing Therapy in Chronic Granulomatous Disease

Prime Medicine Reports First-in-Human Prime Editing Success for Chronic Granulomatous Disease in NEJM